Clarikan SR 500 mg 14 tablets
158£
View analogsTreatment of infectious and inflammatory diseases caused by pathogens sensitive to clarithromycin: infections of the upper respiratory tract and ENT organs (tonsillopharyngitis, otitis media, acute sinusitis); infections of the lower respiratory tract (acute bronchitis, exacerbation of chronic bronchitis, community-acquired bacterial and atypical pneumonia); odontogenic infections; infections of the skin and soft tissues; mycobacterial infections (M.avium complex, M.kansasii, M.marinum, M.leprae) and their prevention in AIDS patients; eradication of Helicobacter pylori in patients with peptic ulcer of the duodenum or stomach (only in combination therapy).
Buy
Product quantities
Form of Release: Tablets
Product Brand:
Marcyrl Pharmaceutical Industries
About the brand
Clarikan SR 500 mg 14 tablets
Composition:
Active Ingredient: Clarithromycin — 500 mg per tablet.
Excipients: Corn starch, microcrystalline cellulose, sodium starch glycolate, purified talc, povidone K-30, magnesium stearate.
Product Description:
- Semi-synthetic macrolide antibiotic with sustained (sustained-release) action in the form of film-coated tablets.
- Clarithromycin suppresses protein synthesis in the microbial cell by binding to the 50S ribosomal subunit of bacteria.
- It exerts predominantly bacteriostatic as well as bactericidal effects.
- It exhibits a broad spectrum of antibacterial activity against Gram-positive (such as Staphylococcus aureus, streptococci, Listeria monocytogenes) and Gram-negative (Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, Legionella pneumophila, Helicobacter pylori) aerobic microorganisms, as well as intracellular pathogens (Mycoplasma pneumoniae, Chlamydia pneumoniae, mycobacteria).
Indications for Use:
- Treatment of infectious and inflammatory diseases caused by microorganisms sensitive to clarithromycin:
- Upper respiratory tract and ENT infections (tonsillopharyngitis, otitis media, acute sinusitis);
- Lower respiratory tract infections (acute bronchitis, exacerbation of chronic bronchitis, community-acquired bacterial and atypical pneumonia);
- Odontogenic infections;
- Skin and soft tissue infections;
- Mycobacterial infections and their prevention in HIV/AIDS patients;
- Eradication of Helicobacter pylori in patients with duodenal or gastric ulcer disease (as part of combination therapy).
Method of Administration and Dosage:
- How to use: Oral administration.
Tablets should be swallowed whole with water, without chewing or crushing. - Adults and adolescents over 12 years: Standard single dose ranges from 250 mg to 1000 mg (0.25–1 g) taken twice daily.
- Children under 12 years: Daily dosage is calculated at 7.5–15 mg/kg body weight per day in 2 divided doses (pediatric formulations such as oral suspension should be used for this age group).
- Patients with renal impairment (creatinine clearance less than 30 mL/min): The dose should be reduced by half or the dosing interval doubled.
- Maximum daily dose: 2000 mg (2 g) for adults; 1000 mg (1 g) for children. Treatment duration is determined by a physician based on clinical indications.
Contraindications:
- History of QT interval prolongation, ventricular arrhythmia, or Torsades de Pointes
- Hypokalemia (risk of QT interval prolongation)
- Severe hepatic impairment occurring concurrently with renal impairment
- History of cholestatic jaundice or hepatitis associated with prior clarithromycin use
- Porphyria
- First trimester of pregnancy
- Lactation (breastfeeding) period
- Concomitant administration with astemizole, cisapride, pimozide, terfenadine, ergot alkaloids (e.g., ergotamine, dihydroergotamine), oral midazolam, HMG-CoA reductase inhibitors/statins extensively metabolized by CYP3A4 (lovastatin, simvastatin), colchicine, ticagrelor, or ranolazine
- Known hypersensitivity to clarithromycin, other macrolide antibiotics, or any inactive excipients
Precautions:
- Cross-resistance between macrolide antibiotics should be taken into account.
- Prolonged use of antibiotics may alter normal intestinal flora, leading to superinfection caused by resistant organisms.
- Severe, persistent diarrhea should be evaluated for the development of pseudomembranous colitis.
- Regular monitoring of prothrombin time and INR is recommended in patients receiving clarithromycin concurrently with warfarin or other oral anticoagulants.
Adverse Reactions / Side Effects:
- Gastrointestinal System: Frequently — diarrhea, nausea, vomiting, dyspepsia, abdominal pain.
- Nervous System and Special Senses: Frequently — dysgeusia (taste disturbance); infrequently — vertigo, hearing impairment, tinnitus; frequency unknown — deafness, ageusia, parosmia, anosmia.
- Skin and Subcutaneous Tissue: Frequently — rash, hyperhidrosis (intense sweating); infrequently — pruritus, urticaria, maculopapular rash, bullous dermatitis; frequency unknown — acne, hemorrhages.
- Cardiovascular System: Frequently — vasodilation.
- Allergic Reactions: Infrequently — hypersensitivity, anaphylactoid reactions.
- General and Local Reactions: Very frequently — phlebitis at injection site (for parenteral forms); frequently — injection site pain and inflammation; infrequently — malaise, asthenia, fatigue, pyrexia, chills, chest pain.
Pregnancy and Lactation:
Use during the first trimester of pregnancy and during breastfeeding is contraindicated.
During the second and third trimesters of pregnancy, use is permissible only if the potential benefit to the mother outweighs the potential risk to the fetus.
Storage Conditions:
Store at a temperature not exceeding 30 °C in a dry place.
Keep out of reach of children.
Packaging:
Cardboard box containing 2 blisters of 7 tablets each.
Tags, Keywords:
Active Ingredients:
No comments yet. Be the first to write one.
Your comment will be published after moderation.
You’ll receive a notification to your email when someone replies.
Русский
English
عربي


